| Literature DB >> 30625201 |
Anna M Polaski1,2, Amy L Phelps2,3, Matthew C Kostek2,4, Kimberly A Szucs2,5, Benedict J Kolber1,2.
Abstract
OBJECTIVE: Increasing evidence purports exercise as a first-line therapeutic for the treatment of nearly all forms of chronic pain. However, knowledge of efficacious dosing respective to treatment modality and pain condition is virtually absent in the literature. The purpose of this analysis was to calculate the extent to which exercise treatment shows dose-dependent effects similar to what is seen with pharmacological treatments.Entities:
Mesh:
Year: 2019 PMID: 30625201 PMCID: PMC6326521 DOI: 10.1371/journal.pone.0210418
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics and data from studies included in analysis.
| INT (broad cat.) | INT (spec. cat.) | METS | Pain State | Review | Authors | Pain outcome | EX (n) | EX Mean (SD) | FREQ. (x/wk) | TIME (min/wk) | IxD (MET-min/wk) | DUR. (wks) | C (n) | C Mean (SD) | Cohen’s d | 95% C.I. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aerobic | Aerobic resistance + ROM /FLEX | 4.3 | FMS | [ | [ | VAS | 28 | 1.5 (1.2) | 3x | 270–540 | 1161–2365 | 6 | 28 | 0.5 (1.2) | 0.83 | [0.28, 1.38] |
| Aerobic | Bicycle | 10.0 | OA | [ | [ | WOMAC | 13 | 18.6 (13.4) | 2x | 80–120 | 800–1200 | 12 | 15 | 34.3 (15.9) | 1.03 | [0.23, 1.83] |
| Aerobic | Conditioning exercise | 9.0 | RA | [ | [ | VAS | 11 | 0.2 (0.6) | 3x | 135–270 | 1215–2430 | 104 | 13 | 0 (0.5) | -0.35 | [-1.16, 0.46] |
| Aerobic | Ergometer exercise | 6.0 | FMS | [ | [ | VAS | 20 | 2.8 (0.7) | 3x | 120 | 720 | 6 | 20 | 1.5 (1.1) | 1.34 | [0.65, 2.04] |
| Aerobic | Ergometer exercise | 2.8 | IC | [ | [ | SF-36 | 32 | 52.8 (23.5) | 2x | 80 | 224 | 24 | 32 | 50.8 (18.5) | 0.09 | [-0.40, 0.58] |
| Aerobic | Gymnastics | 3.8 | NP | [ | [ | VAS | 22 | -9.0 (12.0) | 1x | 45 | 171 | 10 | 22 | -8.0 (18.5) | 0.06 | [-0.53, 0.65] |
| Aerobic | Land aerobic | 7.3 | FMS | [ | [ | VAS | 51 | 0.5 (1.4) | 7x | 70–210 | 511–1533 | 16 | 36 | 0.5 (1.3) | 0.0 | [-0.43, 0.43] |
| Aerobic | Land aerobic | 7.3 | FMS | [ | [ | VAS | 20 | 10.0 (12.7) | 3x | 135 | 985.5 | 14 | 20 | -7.0 (14.6) | 1.22 | [0.54, 1.90] |
| Aerobic | Land aerobic | 7.3 | IC | [ | [ | SF-36 | 17 | 45.2 (9.8) | 2x | 120 | 876 | 12 | 12 | 41.5 (9.8) | 0.38 | [-0.36, 1.13] |
| Aerobic | Land or aquatic aerobic | 5.5 | OA | [ | [ | KOOS | 26 | 24.0 (15.0) | 3x | 180 | 990 | 12 | 26 | 32.0 (18.0) | 0.48 | [-0.08, 1.03] |
| Aerobic | Pole striding | 4.8 | IC | [ | [ | SF-36 | 11 | 60.4 (20.5) | 3x | 90–180 | 432–864 | 24 | 10 | 49.0 (16.1) | 0.61 | [-0.26, 1.49] |
| Aerobic | Qigong | 3.0 | OA | [ | [ | WOMAC | 11 | 71.1 (110.1) | 5x | 150 | 450 | 8 | 10 | 138.2 (112.6) | 0.58 | [-0.30, 1.46] |
| Aerobic | Qigong | 3.0 | NP | [ | [ | VAS | 39 | 30.8 (16.2) | 1-2x | 90–180 | 270–540 | 24 | 39 | 38.9 (18.1) | 0.47 | [0.02, 0.92] |
| Aerobic | Qigong | 3.0 | NP | [ | [ | VAS | 31 | 47.4 (30.8) | 2x | 90 | 270 | 12 | 35 | 54.9 (28.5) | 0.25 | [-0.23, 0.73] |
| Aerobic | Tai Chi | 3.0 | OA | [ | [ | WOMAC | 15 | 5.6 (3.2) | 2x | 120 | 360 | 12 | 5 | 9.2 (3.4) | 1.08 | [0.00, 2.16] |
| Aerobic | Tai Chi | 3.0 | OA | [ | [ | VAS | 22 | 15.4 (5.7) | 3x | 120 | 360 | 12 | 19 | 16.6 (4.7) | 0.23 | [-0.38, 0.85] |
| Aerobic | Tai Chi | 3.0 | OA | [ | [ | VAS | 79 | 37.3 (21.1) | n/a | n/a | n/a | 6 | 74 | 44.4 (23.2) | 0.32 | [0.0, 0.64] |
| Aerobic | Walking | 4.3 | OA | [ | [ | VAS | 144 | 2.1 (0.6) | 3x | 180 | 774 | 72 | 75 | 2.5 (0.6) | 0.53 | [0.81, 0.24] |
| Aerobic | Walking | 3.5 | OA | [ | [ | MPQ | 17 | 1.4 (0.9) | 7x | n/a | n/a | 12 | 17 | 1.2 (1.0) | -0.16 | [-0.83, 0.52] |
| Aerobic | Walking | 4.3 | RA | [ | [ | AIMS | 28 | -1.2 (1.9) | 3x | 180 | 774 | 12 | 28 | -0.7 (1.8) | 0.27 | [-0.26, 0.79] |
| Aerobic | Walking | 3.0 | IC | [ | [ | SF-36 | 27 | 81.5 (18.4) | 3x | n/a | n/a | 12 | 26 | 77.3 (17.8) | 0.23 | [-0.31, 0.77] |
| Aerobic | Walking/ jogging | 6.0 | LBP | [ | [ | MPQ | 24 | 22.4 (13.1) | 5x | 50–100 | 300–600 | 8 | 23 | 26.8 (13.6) | 0.33 | [-0.25, 0.91] |
| Aerobic/ Strength | Bicycle with resistance | 11.0 | RA | [ | [ | VAS | 25 | 0.2 (1.4) | 3x | 180 | 1980 | 12 | 25 | 0.9 (1.2) | 0.53 | [-0.04, 1.09] |
| Aerobic/ Strength | ROM + FLEX | 3.0 | PFPS | [ | [ | VAS | 33 | 0.5 (1.1) | 3x | 60–180 | 180–540 | 16 | 13 | 6.6 (1.4) | 5.03 | [3.82, 6.24] |
| Aerobic/ Strength | Walking + ROM + FLEX | 4.3 | OA | [ | [ | WOMAC | 68 | 4.9 (3.4) | 3x | 180 | 774 | 8 | 43 | 6.2 (4.3) | 0.34 | [-0.04, 0.73] |
| Aquatic | Aquatic aerobic | 5.5 | FMS | [ | [ | VAS | 17 | -18.4 (27.6) | 3x | 180 | 990 | 12 | 17 | 1.0 (17.2) | 0.84 | [0.14, 1.55] |
| Aquatic | Aquatic aerobic | 5.0 | FMS | [ | [ | VAS | 28 | -12.0 (23.0) | 1x | 45 | 225 | 20 | 29 | -2.0 (21.0) | 0.45 | [-0.07, 0.98] |
| Aquatic | Aquatic aerobic | 5.0 | FMS | [ | [ | VAS | 57 | -4.9 (12.9) | 1x | 45 | 225 | 20 | 52 | -0.02 (11.9) | 0.39 | [0.01, 0.76] |
| Aquatic | Aquatic aerobic | 5.3 | OA | [ | [ | WOMAC | 152 | -8.5 (3.7) | 2x | 120 | 636 | 52 | 158 | -9.4 (3.5) | 0.24 | [0.02, 0.47] |
| Aquatic | Aquatic aerobic | 5.5 | RA | [ | [ | AIMS | 40 | -0.6 (1.7) | 3x | 180 | 990 | 12 | 28 | -0.7 (1.8) | -0.06 | [-0.54, 0.43] |
| Aquatic | Aquatic aerobic/ resistance | 5.0 | FMS | [ | [ | VAS | 15 | -3.0 (11.5) | 3x | 180 | 900 | 32 | 15 | 2.0 (13.8) | 0.39 | [-0.33, 1.12] |
| Aquatic | Aquatic resistance | 5.0 | OA | [ | [ | WOMAC | 35 | -10.0 (4.0) | 3x | n/a | n/a | 6 | 35 | 10.0 (4.0) | 0.0 | [-0.47, 0.47] |
| Aquatic | Aquatic resistance | 3.0 | OA | [ | [ | HAQ | 98 | -1.4 (0.7) | 2x | n/a | n/a | 20 | 117 | -1.5 (0.6) | 0.12 | [-0.15, 0.39] |
| Aquatic | Aquatic resistance | 5.0 | OA | [ | [ | VAS | 21 | -43.5 (18.6) | 3x | 150 | 750 | 12 | 22 | -54.9 (25.2) | 0.5 | [-0.10, 1.11] |
| Aquatic | Aquatic resistance | 5.0 | FMS | [ | [ | VAS | 24 | -21.0 (16.5) | 3x | 105 | 525 | 12 | 22 | -18.7 (11.0) | 0.16 | [-0.42, 0.74] |
| Aquatic | Aquatic resistance | 5.0 | FMS | [ | [ | VAS | 29 | -11.4 (11.1) | 3x | 150–210 | 750–1050 | 16 | 24 | 3.3 (15.0) | 1.14 | [0.56, 1.72] |
| Strength | Aerobic resistance | 4.3 | OA | [ | [ | NRS | 45 | 4.02 (2.9) | 1-2x | 30–60 | 129–258 | 8 | 43 | 5.6 (2.8) | 0.55 | [0.13, 0.98] |
| Strength | Ergometer exercise | 6.0 | SCI | [ | [ | SF-36 | 11 | 4.6 (1.7) | 2x | 180–240 | 1080–1440 | 36 | 10 | 6.5 (1.8) | 1.09 | [0.17, 2.01] |
| Strength | Motor control exercise | 3.5 | LBP | [ | [ | NRS | 77 | 46.0 (28.0) | 1-2x | 30–60 | 105–210 | 8 | 77 | 56.0 (26.0) | 0.37 | [0.05, 0.69] |
| Strength | Motor control exercise | 3.5 | LBP | [ | [ | VAS | 36 | 17.2 (15.2) | 1x | 45 | 157.5 | 8 | 35 | 31.2 (19.2) | 0.81 | [0.33, 1.29] |
| Strength | Motor control exercise | 3.5 | LBP | [ | [ | VAS | 21 | 9.4 (19.3) | 5x | 100 | 350 | 4 | 21 | 9.4 (16.2) | 0.0 | [-0.60, 0.60] |
| Strength | Pilates | 3.0 | LBP | [ | [ | VAS | 8 | 30.0 (34.0) | 2x | 120 | 360 | 11 | 9 | 49.0 (25.0) | 0.64 | [-0.33, 1.62] |
| Strength | Pilates | 3.0 | LBP | [ | [ | VAS | 20 | 44.0 (18.0) | 3x | 120 | 360 | 6 | 14 | 48.0 (16.0) | 0.23 | [-0.45, 0.92] |
| Strength | Pilates | 3.0 | LBP | [ | [ | NRS | 43 | 31.0 (23.0) | 2x | 120 | 360 | 6 | 43 | 52.0 (23.0) | 0.91 | [0.47, 1.36] |
| Strength | Pilates | 3.0 | LBP | [ | [ | VAS | 30 | 40.4 (24.2) | 2x | 100 | 300 | 8 | 30 | 51.6 (25.3) | 0.45 | [-0.06, 0.96] |
| Strength | Pilates | 3.0 | LBP | [ | [ | VAS | 15 | 30.9 (16.5) | 6x | 135 | 405 | 8 | 14 | 44.6 (15.1) | 0.86 | [0.10, 1.63] |
| Strength | Pilates | 3.0 | LBP | [ | [ | NRS | 21 | 18.3 (14.3) | 6x | 270 | 810 | 4 | 18 | 33.9 (14.1) | 1.10 | [0.42, 1.77] |
| Strength | ROM + FLEX | 3.0 | SCI | [ | [ | VAS | 40 | 1.4 (1.6) | 3x | n/a | n/a | 12 | 40 | 4.2 (2.7) | 1.26 | [0.78, 1.74] |
| Strength | ROM + FLEX | 2.5 | NP | [ | [ | VAS | 35 | 28.5 (20.8) | 1-2x | n/a | n/a | 24 | 39 | 38.8 (21.6) | 0.49 | [0.02, 0.95] |
| Strength | ROM + FLEX | 2.5 | NP | [ | [ | VAS | 35 | 44.5 (25.7) | 2x | 90 | 225 | 12 | 35 | 54.9 (28.5) | 0.38 | [-0.09, 0.86] |
| Strength | ROM + FLEX | 4.0 | PFPS | [ | [ | VAS | 9 | 2.3 (1.6) | 4x | n/a | n/a | 8 | 5 | 3.5 (1.8) | 0.66 | [-0.47, 1.79] |
| Strength | ROM + FLEX | 4.0 | PFPS | [ | [ | VAS | 9 | 2.04 (1.7) | 4x | n/a | n/a | 8 | 6 | 3.5 (1.8) | 0.78 | [-0.31, 1.86] |
| Strength | ROM + FLEX | 2.5 | PFPS | [ | [ | VAS | 35 | 4.0 (1.3) | 3x | 60 | 150 | 16 | 13 | 6.6 (1.4) | 1.94 | [1.20, 2.69] |
| Strength | Strength | 5.0 | FMS | [ | VAS | 11 | 24.0 (15.0) | 2x | n/a | n/a | 17 | 10 | -25.0 (16.4) | 3.0 | [1.68, 4.32] | |
| Strength | Strength | 5.0 | FMS | [ | VAS | 11 | 24.0 (15.0) | 2x | n/a | n/a | 17 | 10 | -25.0 (16.4) | 3.0 | [1.68, 4.32] | |
| Strength | Strength | 3.5 | FMS | [ | [ | VAS | 30 | -3.94 (2.0) | 3x | 180 | 630 | 16 | 30 | -2.2 (1.6) | 0.99 | [0.46, 1.53] |
| Strength | Strength | 3.5 | OA | [ | [ | VAS | 11 | 37.0 (26.0) | 4x | 180 | 630 | 6 | 13 | 47.2 (20.5) | 0.43 | [-0.39, 1.24] |
| Strength | Strength | 4.0 | OA | [ | [ | VAS | 35 | 3.6 (2.5) | 1x | 60 | 240 | 8 | 39 | 4.1 (2.1) | 0.22 | [-0.24, 0.67] |
| Strength | Strength | 3.5 | OA | [ | [ | VAS | 35 | 26.0 (25.9) | 1-3x | n/a | n/a | 12 | 33 | 43.4 (21.6) | 0.72 | [0.23, 1.21] |
| Strength | Strength | 3.5 | OA | [ | [ | WOMAC | 10 | 10.8 (4.3) | 3x | 90 | 315 | 6 | 6 | 8.3 (4.4) | -0.54 | [-1.57, 0.50] |
| Strength | Strength | 3.5 | OA | [ | [ | VAS | 61 | 22.6 (20.7) | 7x | n/a | n/a | 8 | 56 | 29.6 (23.4) | 0.32 | [0.05, 0.68] |
| Strength | Strength | 3.5 | OA | [ | [ | VAS | 146 | 2.2 (0.7) | 3x | 180 | 630 | 72 | 75 | 2.5 (0.6) | 0.36 | [0.08, 0.64] |
| Strength | Strength | 5.5 | OA | [ | [ | WOMAC | 20 | 3.8 (2.7) | 3x | n/a | n/a | 24 | 25 | 4.4 (3.7) | 0.18 | [-0.41, 0.77] |
| Strength | Strength | 4.5 | OA | [ | [ | WOMAC | 68 | 4.8 (3.1) | 3x | 90–150 | 405–675 | 8 | 30 | 7.1 (3.4) | 0.71 | [0.27, 1.16] |
| Strength | Strength | 3.5 | OA | [ | [ | WOMAC | 36 | 4.2 (3.0) | 3x | 150 | 525 | 8 | 36 | 7.3 (3.4) | 0.96 | [0.47, 1.45] |
| Strength | Strength | 3.0 | NP | [ | [ | VAS | 10 | 3.0 (2.8) | 7x | n/a | n/a | 2 | 10 | 2.6 (2.9) | -0.13 | [-1.01, 0.74] |
| Strength | Strength | 2.5 | NP | [ | [ | VAS | 28 | 1.9 (1.8) | 7x | n/a | n/a | 6 | 33 | 1.7 (1.7) | -0.11 | [-0.62, 0.39] |
| Strength | Strength | 5.0 | NP | [ | [ | VAS | 135 | 2.9 (2.6) | 3x | 90 | 450 | 12 | 130 | 2.7 (2.5) | -0.08 | [-0.32, 0.16] |
| Strength | Strength | 5.0 | LBP | [ | [ | WHYMPI | 31 | 29.0 (17.0) | 1-2x | n/a | n/a | 10 | 23 | 41.0 (15.0) | 0.74 | [0.18, 1.30] |
| Strength | Strength | 3.0 | LBP | [ | [ | VAS | 34 | 23.0 (16.0) | 1-2x | 60–120 | 180–360 | 13 | 35 | 24.0 (17.0) | 0.06 | [-0.41, 0.53] |
| Strength | Strength | 3.0 | LBP | [ | [ | MPQ | 10 | 26.0 (17.0) | 2x | n/a | n/a | 4 | 10 | 30.0 (16.4) | 0.24 | [-0.64, 1.12] |
| Strength | Strength + ROM + FLEX | 3.5 | OA | [ | [ | WOMAC | 55 | 20.6 (17.2) | 2-3x | n/a | n/a | 12 | 54 | 25.3 (18.5) | 0.26 | [-0.12, 0.64] |
| Strength | Strength + ROM + FLEX | 5.0 | OA | [ | [ | WOMAC | 60 | 24.1 (21.7) | 1x | 45 | 225 | 12 | 58 | 27.8 (19.8) | 0.18 | [-0.18, 0.54] |
| Strength | Strength + ROM + FLEX | 3.5 | OA | [ | [ | WOMAC | 25 | 7.0 (7.5) | 1x | 45 | 157.5 | 4 | 25 | 10.0 (7.5) | 0.39 | [-0.17, 0.95] |
| Strength | Strength + ROM + FLEX | 4.0 | OA | [ | [ | VAS | 25 | 38.0 (12.5) | 2x | 100 | 400 | 8 | 27 | 39.7 (12.0) | 0.14 | [-0.41, 0.68] |
| Strength | Strength + ROM + FLEX | 3.5 | LBP | [ | [ | VAS | 14 | 6.0 (17.2) | 2x | 90 | 315 | 16 | 19 | 37.0 (17.2) | 1.80 | [0.99, 2.62] |
INT shows categories for intervention type.
(#) denotes the intervention group for studies that included multiple interventions.
* denotes duplicates found.
EX, exercise (group); FREQ, # of exercise sessions per week; TIME, minutes of exercise per week; IxD, intensity x dose MET-minutes of intervention per week; DUR, # of weeks the intervention lasts; C, control (group); SD, standard deviation; ROM, range of motion exercise; FLEX, flexibility exercise; RA, rheumatoid arthritis; PFPS, patellofemoral pain syndrome; OA, osteoarthritis; FMS, fibromyalgia syndrome; IC, intermittent claudication; NP, neck pain; LBP, low back pain; SCI, spinal cord injury; VAS, visual analog scale; WOMAC, Western Ontario McMaster Osteoarthritis index; SF-36, The Short Form (36) Health Survey; AIMS, Arthritis Impact Measurement Scale; MPQ, McGill Pain Questionnaire; KOOS, Knee Injury and Osteoarthritis Outcome Score; HAQ, The Health Assessment Questionnaire; NRS, Numerical Ratings Scale; WHYMPI, West Haven-Yale Multidimensional Pain Inventory. Cohen’s d is represented as standardized mean effect sizes.
Comprehensive list of results for all univariate correlation analyses performed for pain effect size versus dose of exercise intervention.
| R (N) | |||
|---|---|---|---|
| Analyses | FREQUENCY | TIME | DURATION |
| Neck pain (NP) | -0.6969 (6) | 0.3035 (4) | |
| Fibromyalgia (FMS) | -0.2894 (12) | 0.3739 (8) | -0.1541 (13) |
| Osteoarthritis (OA) | -0.1540 (23) | 0.3703 (16) | 0.0165 (27) |
| Low back pain (LBP) | -0.1979 (10) | 0.1519 (9) | 0.3819 (13) |
| Aquatic exercise | 0.0948 (12) | 0.3519 (10) | -0.0458 (12) |
| Aerobic exercise | -0.0585 (35) | 0.2633 (26) | -0.1002 (36) |
| Strength training | -0.1254 (41) | 0.1202 (27) | 0.1181 (49) |
| Meditative movement | 0.3453 (10) | 0.5610 (10) | -0.2183 (12) |
| Pilates-only | 0.5624 (6) | 0.6718 (6) | -0.3286 (6) |
| Walking/jogging | -0.0074 (8) | -0.0725 (7) | -0.0392 (9) |
| Aquatic aerobic | 0.0194 (7) | 0.0088 (7) | -0.2308 (7) |
Analysis grouping is shown in the left column. R represents value of Pearson’s correlation coefficient. (N) represents the number of individual studies included in the analysis.
**p<0.01.
Results of multivariate linear regression modeling for dose interactions.
| Parameter | Estimate | Std. Err. | DF | T-Stat | p-value |
|---|---|---|---|---|---|
| Intercept | 0.374 | 0.244 | 36 | 1.536 | 0.1333 |
| Dose: FREQUENCY (x/wk) | -0.357 | 0.122 | 36 | -2.913 | 0.0061 |
| Dose: TIME (min/wk) | 0.007 | 0.003 | 36 | 2.660 | 0.0116 |
| Dose: DURATION (wks) | -0.026 | 0.018 | 36 | -1.443 | 0.1575 |
| Sig | 0.743 | 0.114 | 36 | 6.516 | <0.0001 |
| Dur*Time | -0.001 | 0.0002 | 36 | -2.766 | 0.0089 |
| Dur*Freq | 0.042 | 0.014 | 36 | 2.970 | 0.0053 |
Shown are the multiple linear regression coefficients. Model F-statistic = 9.628, p<0.001. Adjusted R2 = 0.552.
Predicted pain effect values using the multiple linear regression model for significant and non-significant studies.
| Intercept | FREQUENCY (x/wk) | TIME (min/wk) | DURATION (wks) | Dur*Time | Dur*Freq | Pain Effect Sig | Pain Effect Not Sig | ||
|---|---|---|---|---|---|---|---|---|---|
| Coefficient | 0.374 | -0.36 | 0.01 | -0.03 | -0.001 | 0.04 | 0.743 | 0 | |
| Less 2 day | 120 | 15 | 1800 | 15 | 0.307 | -0.436 | |||
| Less 1 day | 120 | 15 | 1800 | 30 | 0.547 | -0.196 | |||
| Average Values | 120 | 15 | 1800 | 45 | 0.787 | 0.044 | |||
| Add 1 day | 120 | 15 | 1800 | 60 | 1.027 | 0.284 | |||
| Add 2 day | 120 | 15 | 1800 | 75 | 1.267 | 0.524 | |||
| Add 3 day | 120 | 15 | 1800 | 90 | 1.507 | 0.764 | |||
| Less 1.5 hr | 3 | 15 | 450 | 45 | 1.237 | 0.494 | |||
| Less 1 hr | 3 | 15 | 900 | 45 | 1.087 | 0.344 | |||
| Less 0.5 hr | 3 | 15 | 1350 | 45 | 0.937 | 0.194 | |||
| Average Values | 3 | 15 | 1800 | 45 | 0.787 | 0.044 | |||
| Add 0.5 hr | 3 | 15 | 2250 | 45 | 0.637 | -0.106 | |||
| Add 1 hr | 3 | 15 | 2700 | 45 | 0.487 | -0.256 | |||
| Add 1.5 hr | 3 | 15 | 3150 | 45 | 0.337 | -0.406 | |||
| Less 6 wk | 3 | 120 | 1080 | 27 | 0.967 | 0.224 | |||
| Less 4 wk | 3 | 120 | 1320 | 33 | 0.907 | 0.164 | |||
| Less 2 wk | 3 | 120 | 1560 | 39 | 0.847 | 0.104 | |||
| Average Values | 3 | 120 | 1800 | 45 | 0.787 | 0.044 | |||
| Add 2 wk | 3 | 120 | 2040 | 51 | 0.727 | -0.016 | |||
| Add 4 wk | 3 | 120 | 2280 | 57 | 0.667 | -0.076 | |||
| Add 6 wk | 3 | 120 | 2520 | 63 | 0.607 | -0.136 |
The last two columns show predicted pain effect sizes for significant studies versus non-significant studies as a result of the exercise prescription shown in the second column. The highlighted cells indicate the variables being changed compared to the average values from the included studies.
Results of univariate correlation analyses performed for pain effect size versus INTENSITY x TIME.
| R (N) | |
|---|---|
| Analyses | INTENSITY x DOSE |
| Neck pain (NP) | -0.4768 (5) |
| Fibromyalgia (FMS) | 0.5178 (8) |
| Osteoarthritis (OA) | 0.1426 (16) |
| Low back pain (LBP) | 0.1727 (9) |
| Aquatic exercise | 0.0631 (11) |
| Aerobic exercise | 0.1482 (28) |
| Strength training | -0.0559 (33) |
| Meditative movement | 0.5610 (10) |
| Pilates-only | 0.6718 (6) |
| Walking/jogging | 0.0001 (4) |
| Aquatic aerobic | 0.0126 (7) |
Analysis grouping is shown in the left column. Dose of exercise is represented by TIME in minutes per week. R represents value of Pearson’s correlation coefficient. N represents the number of individual studies included in the analysis.